Related Experiment Video
Updated: Jan 21, 2026

Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial
Lena Rivard1, Paul Khairy1, Mario Talajic1
1Department of Medicine, Université de Montréal, Montréal, Québec, Canada.
Insights
This study investigated if rivaroxaban reduces stroke and cognitive decline in atrial fibrillation (AF) patients. Results will clarify anticoagulation benefits for AF-related neurocognitive impairment.
Area of Science:
- Cardiology
- Neurology
- Clinical Trials
Background:
- Growing evidence links atrial fibrillation (AF) to cognitive decline and dementia.
- Understanding AF's impact on brain health is crucial for preventative strategies.
Purpose of the Study:
- To determine if rivaroxaban, an oral anticoagulant, reduces the risk of stroke, transient ischemic attack (TIA), or cognitive decline.
- To evaluate the efficacy of anticoagulation in patients with nonvalvular AF and low stroke risk.
Main Methods:
- The Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF) is a prospective, multicentric, double-blind, randomized-controlled trial.
- Patients with nonvalvular AF and low stroke risk were randomized to rivaroxaban (15 mg daily) or standard of care.
- Exclusion criteria included high bleeding risk.
Main Results:
- The primary outcome is a composite of stroke, TIA, and cognitive decline (defined as ≥ 3-point decrease in Montreal Cognitive Assessment score).
- Approximately 3250 patients will be enrolled across 130 sites.
- The study aims to reach 609 adjudicated primary outcome events.
Conclusions:
- BRAIN-AF will provide critical data on the effectiveness of rivaroxaban in preventing adverse cerebrovascular and cognitive outcomes in AF patients.
- Findings will inform clinical guidelines for managing AF to preserve cognitive function.
Background:
Compelling evidence showing a link between atrial fibrillation (AF) and cognitive decline and dementia is accumulating.
Methods:
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF) is a prospective, multicentric, double-blind, randomized-controlled trial, recruiting patients with nonvalvular AF and a low risk of stroke. Patients with a high risk of bleeding will be excluded from the study. Participants will be randomized to receive either rivaroxaban (15 mg daily) or standard of care (placebo in patients without vascular disease or acetylsalicylic acid 100 mg daily in patients with vascular disease).
Results:
The primary outcome is the composite of stroke, transient ischemic attack, and cognitive decline (defined by a decrease in the Montreal Cognitive Assessment score ≥ 3 at any follow-up visit after baseline). Approximately 3250 patients will be enrolled in approximately 130 clinical sites until 609 adjudicated primary outcome events have occurred.
Conclusions:
BRAIN-AF determines whether oral anticoagulation therapy with rivaroxaban compared with standard of care reduces the risk of stroke, transient ischemic attack, or cognitive decline in patients with nonvalvular AF and a low risk of stroke.
More Related Videos
Related Concept Videos
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Blind Procedures
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Random Sampling Method
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

